Dermatologic Diseases clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for

  • Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

    open to eligible people ages 18-75

    This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

    at UCLA

  • Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

    open to eligible people ages 16 years and up

    The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. Select specimens may undergo genetic analysis to investigate underlying molecular pathways associated with dysregulated angiogenesis in cutaneous disease. Biospecimens, either previously obtained or newly collected from dermatologic conditions, will be analyzed for angiogenic markers. Discarded skin tissue from surgical or biopsy procedures may also be used, including both diseased and non-diseased tissue from the same donor. Some specimens may also undergo genetic analysis to investigate underlying molecular pathways. De-identified data such as age, sex, race, cause of death, lesion location, and description will be recorded. Currently, specimens are limited to clinically diagnosed lesions not typically biopsied, or lesions already confirmed by prior biopsy.

    at UC Irvine

Our lead scientists for Dermatologic Diseases research studies include .

Last updated: